Effectiveness of paliperidone palmitate one-month long-acting injection in obese vs. non-obese patients

被引：0
作者：
Dorflinger, Charles [1 ]
LeHew, Colleen [1 ]
Carey, Heather [1 ]
Roche-Desilets, Jennifer [1 ]
Burant, Christopher J. [2 ,3 ]
机构：
[1] VA Northeast Ohio Healthcare Syst, Pharm Dept, 10701 East Blvd, Cleveland, OH 44106 USA
[2] VA Northeast Ohio Healthcare Syst, Geriatr Res Educ & Clin Ctr, 10701 East Blvd, Cleveland, OH 44106 USA
[3] Case Western Reserve Univ, Frances Payne Bolton Sch Nursing, 10900 Euclid Ave, Cleveland, OH 44106 USA
来源：
COMPREHENSIVE PSYCHIATRY | 2021年 / 111卷
关键词：
MEDICATION ADHERENCE; SCHIZOPHRENIA; PREVALENCE;
D O I：
10.1016/j.comppsych.2021.152269
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
[No abstract available]
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Paliperidone Palmitate versus Risperidone Long-Acting Injectable in Patients with Schizophrenia: A Meta-Analysis of Efficacy and Safety
    Zhao, Mingjun
    Qin, Bin
    Mao, Yage
    Zhang, Yang
    Zhao, Ruisheng
    Wang, Aiqin
    Wang, Hailing
    Zhao, Jianting
    Wang, Changhong
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2023, 19 : 749 - 757
  • [32] Cumulative Clinical Experience of the Use of Paliperidone Palmitate 3-Monthly Long-Acting Injection in the Treatment of Schizophrenia : A Critical Appraisal
    Garcia-Carmona, Juan Antonio
    Pappa, Sofia
    DRUG HEALTHCARE AND PATIENT SAFETY, 2023, 15 : 113 - 123
  • [33] A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia
    Najarian, Dean
    Sanga, Panna
    Wang, Steven
    Lim, Pilar
    Singh, Arun
    Robertson, Mary Jane
    Cohen, Kristin
    Schotte, Alain
    Milz, Ruth
    Venkatasubramanian, Raja
    T'Jollyn, Huybrecht
    Walling, David P.
    Galderisi, Silvana
    Gopal, Srihari
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2022, 25 (03) : 238 - 251
  • [34] The Comparative Effects of Risperidone Long-Acting Injection and Paliperidone Palmitate on Social Functioning in Schizophrenia: A 6-Month, Open-Label, Randomized Controlled Pilot Trial
    Koshikawa, Yosuke
    Takekita, Yoshiteru
    Kato, Masaki
    Sakai, Shiho
    Onohara, Ai
    Sunada, Naotaka
    Nishida, Keiichiro
    Yoshimura, Masafumi
    Fabbri, Chiara
    Serretti, Alessandro
    Kinoshita, Toshihiko
    NEUROPSYCHOBIOLOGY, 2016, 73 (01) : 35 - 42
  • [35] A 10-Year Observational Study of the Use, Acceptability and Effectiveness of Long-Acting Paliperidone Palmitate: Implications for Clinical Decision Making
    Pappa, Sofia
    Barnett, Joshua
    Mason, Katy
    CNS DRUGS, 2023, 37 (01) : 107 - 116
  • [36] A randomized, prospective, active-controlled study comparing intramuscular long-acting paliperidone palmitate versus oral antipsychotics in patients with schizophrenia at risk of violent behavior
    Wang, Gang
    Huang, Huiteng
    Wang, Yijun
    Yang, Yongde
    Li, Chang
    Luo, Sen
    Li, Yi
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2024, 129
  • [37] Comparison of long-term prognosis between non-obese and obese patients with non-alcoholic fatty liver disease
    Iwaki, Michihiro
    Kessoku, Takaomi
    Tanaka, Kosuke
    Ozaki, Anna
    Kasai, Yuki
    Yamamoto, Atsushi
    Takahashi, Kota
    Kobayashi, Takashi
    Nogami, Asako
    Honda, Yasushi
    Ogawa, Yuji
    Imajo, Kento
    Oyamada, Shunsuke
    Kobayashi, Noritoshi
    Aishima, Shinichi
    Saito, Satoru
    Nakajima, Atsushi
    Yoneda, Masato
    JGH OPEN, 2022, 6 (10): : 696 - 703
  • [38] Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics
    Schreiner, A.
    Bergmans, P.
    Cherubin, P.
    Keim, S.
    Llorca, P-M
    Cosar, B.
    Petralia, A.
    Corrivetti, G.
    Hargarter, L.
    JOURNAL OF PSYCHOPHARMACOLOGY, 2015, 29 (08) : 910 - 922
  • [39] Factors Associated with the Initiation of Long-Acting Injectable Paliperidone Palmitate Versus Aripiprazole Among Medicaid Patients with Schizophrenia: An Observational Study
    Qian Cai
    Charmi Patel
    Edward Kim
    Nancy Connolly
    Ozgur Tunceli
    Antoine C. El Khoury
    Advances in Therapy, 2019, 36 : 858 - 869
  • [40] Factors Associated with the Initiation of Long-Acting Injectable Paliperidone Palmitate Versus Aripiprazole Among Medicaid Patients with Schizophrenia: An Observational Study
    Cai, Qian
    Patel, Charmi
    Kim, Edward
    Connolly, Nancy
    Tunceli, Ozgur
    El Khoury, Antoine C.
    ADVANCES IN THERAPY, 2019, 36 (04) : 858 - 869
12345